± HEALTH Colorectal Cancer (CRC) is a common cause of cancer death and prognostic factors are used to determine manage…+ HEALTH This multicenter study developed and validated an interpretable machine learning model integrating granular n…+ HEALTH Multiple stakeholders need to locate results of registered clinical trials but frequently struggle to find th…+ HEALTH Accurate preoperative glioma grading and molecular subtyping are important for treatment. The vascular microe…+ HEALTH Gastrointestinal endoscopy generates extensive high-resolution video data, posing significant challenges for…+ HEALTH Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) and invasive encapsulat…+ POLICY Artificial intelligence (AI) has the potential to strengthen real-world evidence (RWE) for regulatory decisio…± HEALTH Echocardiography remains the cornerstone of cardiovascular imaging. However, traditional workflows including…
TruaceTracing the truth around AIFriday, August 28, 2026
Subscribe
Policy·G Space·Evidence-backed gain·Published 2026-08-28

AI-Enabled Real-World Evidence in Oncology: A Statistical Perspective for Regulatory Decisions

Abstract: Artificial intelligence (AI) has the potential to strengthen real-world evidence (RWE) for regulatory decision-making, but its contribution varies by application and methodological maturity. RWE remains limited by challenges in data quality, population selection, treatment characterization, outcome assessment, and statistical methodology. Machine learning and generative AI (genAI), combined with causal inference frameworks, may address these challenges. We review applications, limitations, including reproducibil…

TRV-2026-0914Peer-reviewedPermanent record — cite & verify
AI-Enabled Real-World Evidence in Oncology: A Statistical Perspective for Regulatory Decisions

"Barriers to conducting replications of experiment in cancer research" by Authors of the study: Timothy M Errington, Alexandria Denis, Nicole Perfito, Elizabeth Iorns, Brian A Nosek is licensed under CC BY 4.0. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

The quick read

A 2026 review in Therapeutic Innovation & Regulatory Science assessed artificial intelligence for real-world evidence in oncology from a statistical perspective for regulatory decisions. It described RWE as limited by data quality, population selection, treatment characterization, outcome assessment, and statistical methodology, and discussed machine learning and generative AI combined with causal inference frameworks as approaches that may address those challenges.

The relevance for regulation is that stronger RWE could inform approvals and oversight, but the review emphasizes that AI's contribution varies by application and maturity and that issues of reproducibility, bias, transportability, uncertainty quantification, and regulatory acceptability remain unresolved, leaving fit-for-purpose validation as an open priority.

Main points
  • Article reviews AI-enabled RWE in oncology from a statistical perspective for regulatory decisions.
  • RWE is described as limited by data quality, population selection, treatment characterization, outcome assessment, and statistical methodology.
  • Authors discuss machine learning and generative AI combined with causal inference frameworks as potential approaches.
  • Review covers limitations including reproducibility, bias, transportability, uncertainty quantification, and regulatory acceptability.
Gain

Machine learning and generative AI combined with causal inference frameworks may strengthen oncology real-world evidence used for regulatory decisions.

The rundown

The source is a peer-reviewed review in Therapeutic Innovation & Regulatory Science dated 2026-08-26 that examines AI-enabled real-world evidence in oncology for regulatory decisions.

It frames current RWE as constrained by data quality, population selection, treatment characterization, outcome assessment, and statistical methodology, and evaluates machine learning and generative AI with causal inference as possible mitigations.

It also prioritizes methodological needs for fit-for-purpose use, noting that acceptability depends on addressing reproducibility, bias, transportability, and uncertainty quantification.

Sources

Reader signal

How should this claim be treated?

The debate